Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02078492 · ClinicalTrials.gov registry record · Phase 4
A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management
A Phase 4 study, sponsored by Antonios Likourezos.
- Completed
- Registry status
- Phase 4
- Development phase
- 240
- Enrollment target
NCT02078492 is a Phase 4 study that has completed, run by Antonios Likourezos. The registered enrollment target is 240 participants.
The verdict
NCT02078492, a Phase 4 study, has completed, sponsored by Antonios Likourezos.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 240 participants
- Enrollment target
Study Summary
Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
Interventions
- DRUG 10 mg of Ketorolac
- DRUG 15 mg of Ketorolac
- DRUG 30 mg of Ketorolac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02078492
The ClinicalTrials.gov registry entry for NCT02078492 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antonios Likourezos, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 10 mg of Ketorolac is the first listed.
NCT02078492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02078492 about?
NCT02078492 is a clinical study titled "A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management". Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
What is the current status of trial NCT02078492?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 240 participants. The study started on 2014-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02078492?
The interventions under investigation include: 10 mg of Ketorolac (DRUG), 15 mg of Ketorolac (DRUG), 30 mg of Ketorolac (DRUG).
Who is sponsoring clinical trial NCT02078492?
This trial is sponsored by Antonios Likourezos, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.